What is the clinical evidence from this study?

Study design: Other. Population: Herpes Simplex Virus 1 (HSV1) and Coxsackievirus B3 (CVB3) infection. Intervention: Antisense oligonucleotides with phosphothioate internucleotide linkages. Primary outcome: Antiviral activity.

May 1, 1997Nucleosides and Nucleotides

Antiviral Activity of Antisense Oligonucleotides Against Various Targets of Herpes Simplex Virus 1 (Hsv1) and Coxsackievirus B3 (Cvb3) Genome

View Full Paper

Ask AI

Bookmark

Key result

Antisense oligonucleotides carrying exclusively phosphothioate internucleotide linkages demonstrated the highest antiviral activity against HSV1 and CVB3 in cell cultures.

Population

Green monkey kidney cells (GMK) and HeLa cells

Design

Preclinical

Authors

EBEckhard Birch‐HirschfeldFriedrich Schiller University Jena CKChristoph KnorreKiel University ASA. StelznerJena University Hospital

Discussion

Member takes

Implication

May guide antisense oligonucleotide design for HSV1/CVB3; leaves open in vivo efficacy and clinical translation.

Structured PICO

Population

Green monkey kidney cells (GMK) and HeLa cells

Intervention

Antisense oligonucleotides (AS-ODN) with phosphothioate internucleotide linkages directed against the IE-110 gene of HSV1 and CVB3-specific ODNs

Outcome

Antiviral activitysurrogate

Phosphothioate internucleotide linkages enhance the antiviral activity of antisense oligonucleotides against HSV1 and CVB3 in vitro.

Cite This Study

Birch‐Hirschfeld et al. (1997) studied Herpes Simplex Virus 1 (HSV1) and Coxsackievirus B3 (CVB3) infection. Antisense oligonucleotides with phosphothioate internucleotide linkages was evaluated on Antiviral activity. Antisense oligonucleotides carrying exclusively phosphothioate internucleotide linkages demonstrated the highest antiviral activity against HSV1 and CVB3 in cell cultures.

synapsesocial.com/papers/6a9da7509675ea02512a1d58 https://doi.org/10.1080/07328319708002926

View Full Paper

Ask AI

Bookmark